{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:06:44Z","timestamp":1784326004399,"version":"3.55.0"},"reference-count":175,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/ico.0b013e31822480f9","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T09:58:10Z","timestamp":1323251890000},"page":"322-334","source":"Crossref","is-referenced-by-count":33,"title":["Anti-VEGF Therapy With Bevacizumab for Anterior Segment Eye Disease"],"prefix":"10.1097","volume":"31","author":[{"given":"Hamid","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H","family":"Nowroozzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Salouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Nejabat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210204","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R2-18-20210204","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00003226-200307000-00015","article-title":"Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia.","volume":"22","author":"Jin","year":"2003","journal-title":"Cornea"},{"key":"R3-18-20210204","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","article-title":"Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia.","volume":"20","author":"Lee","year":"2001","journal-title":"Cornea"},{"key":"R4-18-20210204","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1442-9071.1996.tb01596.x","article-title":"Experimental corneal neovascularisation using sucralfate and basic fibroblast growth factor.","volume":"24","author":"Loughman","year":"1996","journal-title":"Aust N Z J Ophthalmol"},{"key":"R5-18-20210204","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archopht.1991.01080070117048","article-title":"Altered distribution of basic fibroblast growth factor in diabetic retinopathy.","volume":"109","author":"Hanneken","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R6-18-20210204","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI116877","article-title":"Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.","volume":"92","author":"Meyer-Schwickerath","year":"1993","journal-title":"J Clin Invest"},{"key":"R7-18-20210204","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/bjo.78.9.714","article-title":"Retinal and preretinal localisation of epidermal growth factor, transforming growth factor alpha, and their receptor in proliferative diabetic retinopathy.","volume":"78","author":"Patel","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"R8-18-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy.","volume":"26","author":"Zhang","year":"2007","journal-title":"Prog Retin Eye Res"},{"key":"R9-18-20210204","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.preteyeres.2006.09.001","article-title":"Regulation of corneal angiogenesis in limbal stem cell deficiency.","volume":"25","author":"Ma","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"R10-18-20210204","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.mehy.2006.06.063","article-title":"A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents.","volume":"68","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R11-18-20210204","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jcb.240470305","article-title":"The vascular endothelial growth factor family of polypeptides.","volume":"47","author":"Ferrara","year":"1991","journal-title":"J Cell Biochem"},{"key":"R12-18-20210204","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1046\/j.1523-1755.2000.07718.x","article-title":"Role of vascular endothelial growth factor in diabetic vascular complications.","volume":"77","author":"Aiello","year":"2000","journal-title":"Kidney Int Suppl"},{"key":"R13-18-20210204","first-page":"1029","article-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.","volume":"146","author":"Dvorak","year":"1995","journal-title":"Am J Pathol"},{"key":"R14-18-20210204","first-page":"293","article-title":"Stimulation of endothelial cell migration by vascular permeability factor\/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.","volume":"149","author":"Senger","year":"1996","journal-title":"Am J Pathol"},{"key":"R15-18-20210204","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.1312256","article-title":"The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.","volume":"255","author":"de Vries","year":"1992","journal-title":"Science"},{"key":"R16-18-20210204","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1247\/csf.26.25","article-title":"Structure and function of VEGF\/VEGF-receptor system involved in angiogenesis.","volume":"26","author":"Shibuya","year":"2001","journal-title":"Cell Struct Funct"},{"key":"R17-18-20210204","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/138945011794182674","article-title":"Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.","volume":"12","author":"Campa","year":"2011","journal-title":"Curr Drug Targets"},{"key":"R18-18-20210204","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/CCO.0b013e32833edc0c","article-title":"Bevacizumab: current updates in treatment.","volume":"22","author":"Van Meter","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"R19-18-20210204","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","article-title":"The role of vascular endothelial growth factor in ocular health and disease.","volume":"25","author":"Adamis","year":"2005","journal-title":"Retina"},{"key":"R20-18-20210204","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"R21-18-20210204","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R22-18-20210204","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2174\/092986706777585059","article-title":"Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.","volume":"13","author":"Ranieri","year":"2006","journal-title":"Curr Med Chem"},{"key":"R23-18-20210204","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R24-18-20210204","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00006982-200603000-00017","article-title":"Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection.","volume":"26","author":"Davidorf","year":"2006","journal-title":"Retina"},{"key":"R25-18-20210204","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3928\/1542-8877-20060301-11","article-title":"Intravitreal bevacizumab in a patient with neovascular glaucoma.","volume":"37","author":"Kahook","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R26-18-20210204","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review.","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R27-18-20210204","first-page":"91","article-title":"Factors affecting the outcome of corneal transplantation.","volume":"63","author":"Coster","year":"1981","journal-title":"Ann R Coll Surg Engl"},{"key":"R29-18-20210204","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0161-6420(88)33211-2","article-title":"Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization.","volume":"95","author":"Huang","year":"1988","journal-title":"Ophthalmology"},{"key":"R30-18-20210204","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0161-6420(86)33581-4","article-title":"Corneal argon laser photocoagulation for neovascularization in penetrating keratoplasty.","volume":"93","author":"Nirankari","year":"1986","journal-title":"Ophthalmology"},{"key":"R31-18-20210204","first-page":"2148","article-title":"Fine needle diathermy occlusion of corneal vessels.","volume":"41","author":"Pillai","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-18-20210204","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00003226-200009000-00014","article-title":"Changing concepts in the management of severe ocular surface disease over twenty-five years.","volume":"19","author":"Holland","year":"2000","journal-title":"Cornea"},{"key":"R33-18-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R34-18-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R35-18-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R36-18-20210204","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis.","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"R37-18-20210204","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1600-0420.2006.00659.x","article-title":"Ocular angiogenesis: the role of growth factors.","volume":"84","author":"Kvanta","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"R38-18-20210204","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00417-010-1442-6","article-title":"Features of corneal neovascularization and lymphangiogenesis induced by different etiological factors in mice.","volume":"249","author":"Shi","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R39-18-20210204","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1600-0420.2004.00312.x","article-title":"Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.","volume":"82","author":"Gan","year":"2004","journal-title":"Acta Ophthalmol Scand"},{"key":"R40-18-20210204","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R41-18-20210204","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","article-title":"Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision.","volume":"103","author":"Cursiefen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R42-18-20210204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R43-18-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R44-18-20210204","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1006\/exer.2002.2075","article-title":"Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA.","volume":"75","author":"Lai","year":"2002","journal-title":"Exp Eye Res"},{"key":"R45-18-20210204","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R46-18-20210204","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1167\/iovs.01-1277","article-title":"VEGF-dependent conjunctivalization of the corneal surface.","volume":"44","author":"Joussen","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R47-18-20210204","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"R48-18-20210204","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"R49-18-20210204","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization.","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"},{"key":"R50-18-20210204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/dev.114.2.521","article-title":"Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.","volume":"114","author":"Breier","year":"1992","journal-title":"Development"},{"key":"R51-18-20210204","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization.","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"R52-18-20210204","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J Clin Invest"},{"key":"R53-18-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":"The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas.","volume":"34","author":"Oh","year":"2009","journal-title":"Curr Eye Res"},{"key":"R54-18-20210204","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00003226-200101000-00018","article-title":"Leukocytes in the early events of corneal neovascularization.","volume":"20","author":"Gan","year":"2001","journal-title":"Cornea"},{"key":"R55-18-20210204","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.colsurfb.2007.06.013","article-title":"The expression patterns of vascular endothelial growth factor and thrombospondin 2 after corneal alkali burn.","volume":"60","author":"Yan","year":"2007","journal-title":"Colloids Surf B Biointerfaces"},{"key":"R56-18-20210204","first-page":"1112","article-title":"Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea.","volume":"40","author":"Edelman","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R57-18-20210204","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea.","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr Eye Res"},{"key":"R58-18-20210204","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1755-3768.2008.01349.x","article-title":"Development of new lymphatic vessels in alkali-burned corneas.","volume":"87","author":"Ling","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R59-18-20210204","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"R60-18-20210204","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","article-title":"Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.","volume":"27","author":"Hurmeric","year":"2008","journal-title":"Cornea"},{"key":"R61-18-20210204","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R62-18-20210204","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":"Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R63-18-20210204","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1167\/iovs.08-1997","article-title":"Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R64-18-20210204","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00417-008-0976-3","article-title":"Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization.","volume":"247","author":"Han","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R65-18-20210204","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","article-title":"The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea.","volume":"79","author":"Barros","year":"2007","journal-title":"An Acad Bras Cienc"},{"key":"R66-18-20210204","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ajo.2008.09.022","article-title":"The inhibitory effects of trastuzumab on corneal neovascularization.","volume":"147","author":"Guler","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R67-18-20210204","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/02713680903429007","article-title":"Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.","volume":"35","author":"Avisar","year":"2010","journal-title":"Curr Eye Res"},{"key":"R68-18-20210204","first-page":"2326","article-title":"Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.","volume":"15","author":"Dratviman-Storobinsky","year":"2009","journal-title":"Mol Vis"},{"key":"R69-18-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R70-18-20210204","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R71-18-20210204","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00004397-200604620-00005","article-title":"Herpes simplex ocular inflammatory disease.","volume":"46","author":"Green","year":"2006","journal-title":"Int Ophthalmol Clin"},{"key":"R72-18-20210204","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0002-9440(10)61777-4","article-title":"Control of stromal keratitis by inhibition of neovascularization.","volume":"159","author":"Zheng","year":"2001","journal-title":"Am J Pathol"},{"key":"R73-18-20210204","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.preteyeres.2006.05.001","article-title":"Herpes simplex keratitis.","volume":"25","author":"Kaye","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"R74-18-20210204","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0161-6420(94)31087-6","article-title":"Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis.","volume":"101","author":"Wilhelmus","year":"1994","journal-title":"Ophthalmology"},{"key":"R75-18-20210204","doi-asserted-by":"crossref","first-page":"8944","DOI":"10.1073\/pnas.132605599","article-title":"DNA containing CpG motifs induces angiogenesis.","volume":"99","author":"Zheng","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R76-18-20210204","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.mehy.2007.01.032","article-title":"Therapeutic potential of bevacizumab (Avastin) in herpetic stromal keratitis (HSK).","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R77-18-20210204","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.175.1.509","article-title":"Application of plasmid DNA encoding IL-18 diminishes development of herpetic stromal keratitis by antiangiogenic effects.","volume":"175","author":"Kim","year":"2005","journal-title":"J Immunol"},{"key":"R78-18-20210204","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","article-title":"Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.","volume":"27","author":"Carrasco","year":"2008","journal-title":"Cornea"},{"key":"R79-18-20210204","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.4049\/jimmunol.177.6.4122","article-title":"Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects.","volume":"177","author":"Kim","year":"2006","journal-title":"J Immunol"},{"key":"R80-18-20210204","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00003226-200307000-00008","article-title":"Outcomes of repeat penetrating keratoplasty and risk factors for graft failure.","volume":"22","author":"Weisbrod","year":"2003","journal-title":"Cornea"},{"key":"R81-18-20210204","first-page":"2034","article-title":"Corneal graft rejection: incidence, manifestation, and interaction of clinical subtypes.","volume":"24","author":"Pleyer","year":"1992","journal-title":"Transplant Proc"},{"key":"R82-18-20210204","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archopht.121.8.1087","article-title":"Risk factors for various causes of failure in initial corneal grafts.","volume":"121","author":"Price","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R83-18-20210204","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ophtha.2006.12.012","article-title":"Corneal transplant survival after onset of severe endothelial rejection.","volume":"114","author":"Wagoner","year":"2007","journal-title":"Ophthalmology"},{"key":"R84-18-20210204","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"Inhibition of angiogenesis in the anterior chamber of the eye [in German].","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"key":"R85-18-20210204","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00417-002-0496-5","article-title":"Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study.","volume":"240","author":"Kuchle","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R86-18-20210204","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-006-0410-7","article-title":"Clear graft survival and immune reactions following emergency keratoplasty.","volume":"245","author":"Maier","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R87-18-20210204","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0161-6420(94)31138-9","article-title":"Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group.","volume":"101","author":"Maguire","year":"1994","journal-title":"Ophthalmology"},{"key":"R88-18-20210204","first-page":"2127","article-title":"Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.","volume":"43","author":"Cursiefen","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R89-18-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.eye.6700636","article-title":"Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching.","volume":"18","author":"Reinhard","year":"2004","journal-title":"Eye (Lond)"},{"key":"R90-18-20210204","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s004170100285","article-title":"Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years results of a randomized prospective clinical trial.","volume":"239","author":"Reinhard","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R91-18-20210204","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00347-007-1517-x","article-title":"Systemic immunosuppressives after penetrating keratoplasty [in German].","volume":"104","author":"Reis","year":"2007","journal-title":"Ophthalmologe"},{"key":"R92-18-20210204","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00003226-200211000-00007","article-title":"Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization.","volume":"21","author":"Gordon","year":"2002","journal-title":"Cornea"},{"key":"R93-18-20210204","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00003226-200307000-00018","article-title":"Photodynamic therapy of corneal neovascularization with verteporfin.","volume":"22","author":"Fossarello","year":"2003","journal-title":"Cornea"},{"key":"R94-18-20210204","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/exer.1998.0527","article-title":"Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization.","volume":"67","author":"Gohto","year":"1998","journal-title":"Exp Eye Res"},{"key":"R95-18-20210204","first-page":"65","article-title":"Four years experience with triple procedures in herpes-afflicted eyes.","volume":"2","author":"Sundmacher","year":"1993","journal-title":"Ger J Ophthalmol"},{"key":"R96-18-20210204","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4049\/jimmunol.0903180","article-title":"Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation.","volume":"184","author":"Dietrich","year":"2010","journal-title":"J Immunol"},{"key":"R97-18-20210204","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1442-9071.2009.02178.x","article-title":"Crucial role of corneal lymphangiogenesis for allograft rejection in alkali-burned cornea bed.","volume":"37","author":"Ling","year":"2009","journal-title":"Clin Experiment Ophthalmol"},{"key":"R98-18-20210204","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08820530902801320","article-title":"Corneal lymphangiogenesis: implications in immunity.","volume":"24","author":"Patel","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"R99-18-20210204","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1097\/00007890-199812150-00016","article-title":"Effect of a topically applied neutralizing antibody against vascular endothelial growth factor on corneal allograft rejection of rat.","volume":"66","author":"Yatoh","year":"1998","journal-title":"Transplantation"},{"key":"R100-18-20210204","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R101-18-20210204","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bjo.2008.145128","article-title":"Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation.","volume":"93","author":"Bachmann","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R102-18-20210204","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1167\/iovs.09-3745","article-title":"Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival.","volume":"51","author":"Dastjerdi","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R103-18-20210204","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.ophtha.2007.05.016","article-title":"Bevacizumab for graft rejection.","volume":"114","author":"Harooni","year":"2007","journal-title":"Ophthalmology"},{"key":"R104-18-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R105-18-20210204","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts.","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R106-18-20210204","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","article-title":"Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery.","volume":"27","author":"Gerten","year":"2008","journal-title":"Cornea"},{"key":"R107-18-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology.","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"key":"R108-18-20210204","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors.","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"R109-18-20210204","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/sj.eye.6701811","article-title":"Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis.","volume":"20","author":"Abu EEl-Asrar","year":"2006","journal-title":"Eye (Lond)"},{"key":"R110-18-20210204","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1398-9995.2007.01593.x","article-title":"Distinct association of genetic variations of vascular endothelial growth factor, transforming growth factor-beta, and fibroblast growth factor receptors with atopy and airway hyperresponsiveness.","volume":"63","author":"Park","year":"2008","journal-title":"Allergy"},{"key":"R111-18-20210204","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jaci.2005.12.1328","article-title":"Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population.","volume":"117","author":"Park","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R112-18-20210204","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome.","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"R113-18-20210204","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0002-9394(88)90706-4","article-title":"Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium.","volume":"106","author":"Hayasaka","year":"1988","journal-title":"Am J Ophthalmol"},{"key":"R114-18-20210204","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00003226-200103000-00011","article-title":"Halting pterygium recurrence by postoperative 5-fluorouracil.","volume":"20","author":"Pikkel","year":"2001","journal-title":"Cornea"},{"key":"R115-18-20210204","first-page":"1963","article-title":"Active matrilysin (MMP-7) in human pterygia: potential role in angiogenesis.","volume":"42","author":"Di Girolamo","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R116-18-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1076\/ceyr.25.1.17.9959","article-title":"Angiogenesis in pterygium: morphometric and immunohistochemical study.","volume":"25","author":"Marcovich","year":"2002","journal-title":"Curr Eye Res"},{"key":"R117-18-20210204","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ophtha.2005.01.023","article-title":"Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia.","volume":"112","author":"Gebhardt","year":"2005","journal-title":"Ophthalmology"},{"key":"R118-18-20210204","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/ICO.0b013e3181644581","article-title":"Vascular endothelial growth factor gene 460 polymorphism is associated with pterygium formation in female patients.","volume":"27","author":"Tsai","year":"2008","journal-title":"Cornea"},{"key":"R119-18-20210204","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.mehy.2007.01.047","article-title":"Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia.","volume":"69","author":"Hosseini","year":"2007","journal-title":"Med Hypotheses"},{"key":"R120-18-20210204","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/ICO.0b013e3181822615","article-title":"Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium.","volume":"28","author":"Wu","year":"2009","journal-title":"Cornea"},{"key":"R121-18-20210204","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/02713680903395273","article-title":"Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.","volume":"35","author":"Fallah","year":"2010","journal-title":"Curr Eye Res"},{"key":"R122-18-20210204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/02713680701799101","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.","volume":"33","author":"Bahar","year":"2008","journal-title":"Curr Eye Res"},{"key":"R123-18-20210204","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000252980","article-title":"Preliminary results of subconjunctival bevacizumab in primary pterygium excision.","volume":"43","author":"Razeghinejad","year":"2010","journal-title":"Ophthalmic Res"},{"key":"R124-18-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1076\/ceyr.23.1.1.5422","article-title":"Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear.","volume":"23","author":"Mastyugin","year":"2001","journal-title":"Curr Eye Res"},{"key":"R125-18-20210204","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0301-4738.29505","article-title":"Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity.","volume":"55","author":"Shah","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"R126-18-20210204","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.4049\/jimmunol.158.10.4992","article-title":"Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposis sarcoma-derived spindle cells.","volume":"158","author":"Nakamura","year":"1997","journal-title":"J Immunol"},{"key":"R127-18-20210204","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bjo.2006.109702","article-title":"Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells.","volume":"91","author":"Peters","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R128-18-20210204","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0039-6257(82)90081-9","article-title":"Pharmacokinetics of topically applied ophthalmic drugs.","volume":"26","author":"Shell","year":"1982","journal-title":"Surv Ophthalmol"},{"key":"R129-18-20210204","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.","volume":"50","author":"Nomoto","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R130-18-20210204","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization.","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"R131-18-20210204","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"R132-18-20210204","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"27","author":"Doctor","year":"2008","journal-title":"Cornea"},{"key":"R133-18-20210204","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"key":"R134-18-20210204","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.","volume":"288","author":"Lin","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R135-18-20210204","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","article-title":"Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).","volume":"26","author":"Shahar","year":"2006","journal-title":"Retina"},{"key":"R136-18-20210204","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1167\/iovs.06-0433","article-title":"Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.","volume":"47","author":"Costa","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R137-18-20210204","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide.","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R138-18-20210204","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajo.2006.02.045","article-title":"Intracameral bevacizumab for iris rubeosis.","volume":"142","author":"Grisanti","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R139-18-20210204","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/ICO.0b013e3181861cc9","article-title":"Bevacizumab (avastin) for corneal neovascularizationcorneal light shield soaked application.","volume":"28","author":"Mackenzie","year":"2009","journal-title":"Cornea"},{"issue":"suppl 1","key":"R140-18-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","article-title":"Targeted therapy of colorectal cancer: clinical experience with bevacizumab.","volume":"9","author":"Fernando","year":"2004","journal-title":"Oncologist"},{"issue":"suppl 1","key":"R141-18-20210204","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1634\/theoncologist.9-suppl_1-36","article-title":"Maximizing the potential of bevacizumab in cancer treatment.","volume":"9","author":"Bergsland","year":"2004","journal-title":"Oncologist"},{"key":"R142-18-20210204","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"R143-18-20210204","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases.","volume":"41","author":"Lynch","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R144-18-20210204","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1600-0420.1997.tb00623.x","article-title":"Vascular endothelial growth factor (VEGF) in normal human corneal epithelium: detection and physiological importance.","volume":"75","author":"van Setten","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"key":"R145-18-20210204","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1167\/iovs.07-1418","article-title":"Vascular endothelial growth factor mediates corneal nerve repair.","volume":"49","author":"Yu","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R146-18-20210204","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1442-9071.2007.01521.x","article-title":"Bevacizumab (Avastin) for the treatment of neovascular glaucoma.","volume":"35","author":"Chilov","year":"2007","journal-title":"Clin Experiment Ophthalmol"},{"key":"R147-18-20210204","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/bies.20092","article-title":"VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection.","volume":"26","author":"Storkebaum","year":"2004","journal-title":"Bioessays"},{"key":"R148-18-20210204","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1172\/JCI200317977","article-title":"VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia.","volume":"111","author":"Sun","year":"2003","journal-title":"J Clin Invest"},{"key":"R149-18-20210204","first-page":"2115","article-title":"Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes.","volume":"40","author":"Kim","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R150-18-20210204","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1523\/JNEUROSCI.16-19-06089.1996","article-title":"Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells.","volume":"16","author":"Yang","year":"1996","journal-title":"J Neurosci"},{"key":"R151-18-20210204","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am J Pathol"},{"key":"R152-18-20210204","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1167\/iovs.06-0828","article-title":"Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.","volume":"48","author":"Inan","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R153-18-20210204","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00347-007-1569-y","article-title":"Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells [in German].","volume":"104","author":"Kernt","year":"2007","journal-title":"Ophthalmologe"},{"key":"R154-18-20210204","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","article-title":"Safety profile of topical VEGF neutralization at the cornea.","volume":"50","author":"Bock","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R155-18-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R156-18-20210204","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","article-title":"Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).","volume":"246","author":"Wu","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R157-18-20210204","first-page":"579","article-title":"Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review [in Spanish].","volume":"83","author":"Martinez-Carpio","year":"2008","journal-title":"Arch Soc Esp Oftalmol"},{"key":"R158-18-20210204","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00417-007-0754-7","article-title":"Intraocular inflammation following intravitreal injection of bevacizumab.","volume":"246","author":"Bakri","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R159-18-20210204","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ophtha.2008.05.007","article-title":"Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.","volume":"115","author":"Wickremasinghe","year":"2008","journal-title":"Ophthalmology"},{"key":"R160-18-20210204","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/bjo.2008.138479","article-title":"Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin).","volume":"93","author":"Georgopoulos","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R162-18-20210204","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/eye.2009.143","article-title":"Bilateral intraocular inflammation after intravitreal bevacizumab in Behcets disease.","volume":"24","author":"Bae","year":"2010","journal-title":"Eye (Lond)"},{"key":"R163-18-20210204","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/IAE.0b013e3181633fee","article-title":"Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.","volume":"28","author":"Mason","year":"2008","journal-title":"Retina"},{"key":"R164-18-20210204","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents.","volume":"146","author":"Kim","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R165-18-20210204","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3129\/i07-172","article-title":"Short-term intraocular pressure changes after intravitreal injection of bevacizumab.","volume":"42","author":"Hollands","year":"2007","journal-title":"Can J Ophthalmol"},{"key":"R166-18-20210204","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.","volume":"95","author":"Good","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"R168-18-20210204","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajo.2008.06.002","article-title":"Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study.","volume":"146","author":"Chiang","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R169-18-20210204","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/ICO.0b013e318180e572","article-title":"Effect of intracameral bevacizumab injection on corneal endothelium in rabbits.","volume":"27","author":"Park","year":"2008","journal-title":"Cornea"},{"key":"R170-18-20210204","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/jop.2009.0056","article-title":"Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation.","volume":"25","author":"Hosny","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"R171-18-20210204","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s10384-009-0790-4","article-title":"Anterior ischemic optic neuropathy following intravitreal bevacizumab.","volume":"54","author":"Huang","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"R172-18-20210204","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/0301-4738.64142","article-title":"Non-arteritic ischemic optic neuropathy followed by intravitreal bevacizumab injection: is there an association?","volume":"58","author":"Bodla","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"R173-18-20210204","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/WNO.0b013e3181a58fd1","article-title":"Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab.","volume":"29","author":"Hosseini","year":"2009","journal-title":"J Neuroophthalmol"},{"key":"R174-18-20210204","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/j.1755-3768.2009.01572.x","article-title":"Early loss of pregnancy after intravitreal bevacizumab injection.","volume":"88","author":"Petrou","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R175-18-20210204","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00417-009-1171-x","article-title":"Fever after intravitreal anti-VEGF injections.","volume":"248","author":"Ladas","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R176-18-20210204","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/ICO.0b013e318189137a","article-title":"Herpetic epithelial keratitis after intravitreal injection of bevacizumab (Avastin).","volume":"28","author":"Khalili","year":"2009","journal-title":"Cornea"},{"key":"R177-18-20210204","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10384-009-0784-2","article-title":"Cytomegalovirus retinitis after subtenon triamcinolone acetonide and intravitreal injection of anti-vascular endothelial growth factor in an immunocompetent patient with age-related macular degeneration and diabetes mellitus.","volume":"54","author":"Toyokawa","year":"2010","journal-title":"Jpn J Ophthalmol"},{"key":"R178-18-20210204","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3928\/1542-8877-20060301-12","article-title":"Needle bleb revision of encapsulated filtering bleb with bevacizumab.","volume":"37","author":"Kahook","year":"2006","journal-title":"Ophthalmic Surg Lasers Imaging"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-201203000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T01:47:42Z","timestamp":1742003262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201203000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":175,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e31822480f9","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}